Matthew Huddleston

Company: Enable Injections Inc.

Job title: Chief Technology Officer

Seminars:

Patient-enabled Therapy for Advanced Parkinson’s Disease – A Case Study with Serina Therapeutics’ SER-252 + Enable Injections’ enFuse Wearable Drug Delivery Platform 10:45 am

SER-252 is a long-acting POZ-polymer conjugate of apomorphine, a potent dopamine agonist capable of treating the advanced stages of Parkinson's disease  The enFuse Wearable Drug Delivery Platform allows for large volume administration (~ 25 mL) in the comfort of the patient's home, without the need for a healthcare provider to assist in delivery  SER-252 +…Read more

day: Day 1